BRAF and melanoma: Experiments using melanoma cell lines have identified HSP70 and HSP110 inhibitors that may be repurposed to treat CM15 and a small clinical trial of combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma had promising results16.